Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination Therapy for COVID-19
NCT04276688Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon beta-1b and ribavirin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Time to negative nasopharyngeal swab 2019-n-CoV coronavirus viral RT-PCR up to 1 month. Started Feb 2020; status: completed.
02
Drugs
interferon beta-1bribavirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04276688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276688.